Sarepta Therapeutics, Inc. Common Stock (DE) Earnings Dividend

Sarepta Therapeutics, Inc. Common Stock (DE)’s revenue fell -34.34% since last year same period to $401.25Mn in the Q2 2026. On a quarterly growth basis, Sarepta Therapeutics, Inc. Common Stock (DE) has generated -45.09% fall in its revenue since last 3-months.

Sarepta Therapeutics, Inc. Common Stock (DE)’s net profit fell -102.48% since last year same period to $-4.89Mn in the Q2 2026. On a quarterly growth basis, Sarepta Therapeutics, Inc. Common Stock (DE) has generated -101.48% fall in its net profits since last 3-months.

Sarepta Therapeutics, Inc. Common Stock (DE)’s net profit margin fell -103.78% since last year same period to -1.22% in the Q2 2026. On a quarterly growth basis, Sarepta Therapeutics, Inc. Common Stock (DE) has generated -102.69% fall in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc. Common Stock (DE)’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a -11.76% fall from last quarter’s estimates.

Sarepta Therapeutics, Inc. Common Stock (DE)’s earning per share (EPS) estimates for the current year stand at 0.3.

Sarepta Therapeutics, Inc. Common Stock (DE)’s earning per share (EPS) fell -79.21% since last year same period to 0.42 in the Q2 2026. This indicates that the Sarepta Therapeutics, Inc. Common Stock (DE) has generated -79.21% annual rate of fall in its earning per share (EPS) in the last 4 quarters.